This study aims to better understand the role of immune system cells in lung diseases such as lung cancer, sarcoidosis, and chronic obstructive pulmonary disease (COPD).
The investigators are studying how these immune cells can sometimes help the body defend itself, but in other cases may contribute to cancer growth or long-term lung inflammation.
Although recent treatments like immunotherapy have improved cancer care, only a small proportion of patients currently benefit from these therapies. One goal of this research is to understand why some patients do not respond or develop resistance to treatment.
The knowledge gained from this study may help researchers develop more effective and personalized treatments for people with lung diseases in the future.
Diagnosis of lung cancer
Presence of precancerous lung lesions
Patients with a chronic inflammatory lung disease (sarcoidosis or chronic obstructive pulmonary disease [COPD]) prior to any treatment
Control group: individuals without known lung disease
Systemic corticosteroid therapy > 10 mg/day prednisone (or equivalent)
Acute infection at the time of inclusion
Refusal or inability to provide informed consent (or assent, when applicable)
Chronic inflammatory lung disease currently treated with immunosuppressive therapy
Parallel
Peripheral Blood Collection for Immune Profiling
Other interventionParticipants provide biological samples for immune profiling and translational research. Samples include peripheral blood and, when available from routine clinical care, additional specimens such as tumor tissue or rlymph node, bone marrow. No experimental treatments are given. Collected samples are analyzed to characterize immune cell populations and their functional and molecular features, with the aim of studying immune mechanisms involved in lung cancer, sarcoidosis, and COPD, as well as factors associated with disease progression and treatment response. All medical care and treatment decisions remain independent of study participation.
6
Treatment groupsSee each treatment group below.
Progression free survival
median Progression free survival
Click on the lead sponsor to view all of their trials.
